等待開盤 01-12 09:30:00 美东时间
+0.033
+4.71%
Gainers Athira Pharma (NASDAQ:ATHA) stock rose 70.0% to $7.03 during Thursday'...
2025-12-19 01:06
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Elutia Inc. announced it will release its third quarter 2025 financial results after market close on November 6, 2025. A conference call and webcast will be held on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. Registration is required to access the dial-in number and personalized PIN. A live and archived webcast will be available on the Elutia website. For more information, visit the "Investors" section at investors.elutia.com...
2025-10-23 20:05
Elutia Inc.'s CEO, Dr. Randy Mills, will present at the LD Micro Main Event XIX in San Diego on October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET). The presentation will be available via live webcast. Elutia management will also hold 1x1 investor meetings. Interested investors can contact an LD Micro representative or email IR@elutia.com. Elutia specializes in drug-eluting biomatrix technologies aimed at improving compatibility between medical devi...
2025-10-14 20:05
Elutia Inc. appoints Guido J. Neels to its Board of Directors, bringing over 40 years of medical technology leadership experience. Neels, an Operating Partner at EW Healthcare Partners, will also join the audit committee. The company thanks W. Matthew Zuga and Maybelle Jordan for their service as they step down. Neels' expertise is expected to support Elutia's strategic transformation and innovation in drug-eluting biomatrix technology for breast...
2025-10-10 12:00
Elutia Inc. sold its BioEnvelope business to Boston Scientific for $88 million and plans to use the proceeds to develop and launch NXT-41x, a biomatrix targeting mastectomy reconstruction infections. The product aims to reduce complications in breast reconstruction, a $1.5 billion U.S. market. Elutia expects to bring NXT-41x to market by mid-2027.
2025-10-01 12:41
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management -GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Elutia Inc.
2025-09-16 20:17
Elutia Inc. announced the publication of clinical and preclinical data supporting the use of an antibiotic-eluting biologic envelope for CIEDs, showing reduced procedural difficulty and effective bacterial eradication. The study highlights the envelope's ability to improve surgical access and promote tissue remodeling, addressing two key challenges in CIED procedures. These findings lay the groundwork for future applications in surgical settings ...
2025-09-16 12:00
今日重点评级关注:瑞银:上调Gossamer Bio评级至"买入",目标价从1.25美元升至9美元;Canaccord Genuity:维持Corcept Therapeutics"买入"评级,目标价从137美元升至140美元
2025-09-11 10:06
(来源:医疗器械创新网) 01 监管政策与招投标 (一)监管政策 三部门联合建立常态化巡回医疗制度,82 支医疗队赴基层 国家卫健委、国家中医药局、国家疾控局联...
2025-09-11 07:00